FDA Approves Ilumya for Active Psoriatic Arthritis

Sun Pharmaceutical Industries announced that the U.S. Food and Drug Administration approved a supplemental Biologics License Application for Ilumya, also known as tildrakizumab-asmn, for the treatment of adults with active psoriatic arthritis.

Securities reported the announcement on October 30, 2026. According to the publisher, the FDA action expands Ilumya beyond its previously reported indication for moderate-to-severe plaque psoriasis.

FDA action expands reported Ilumya use

The newly reported FDA-approved use is for adults with active psoriatic arthritis. Securities identified Ilumya as an IL-23 inhibitor and reported that the approval was granted through a supplemental Biologics License Application.

Sun Pharmaceutical Industries is the company named in the announcement. The central event is the FDA approval of the supplemental application for Ilumya in active psoriatic arthritis, rather than a new medicine approval.

Securities also noted that Ilumya already had an FDA indication for moderate-to-severe plaque psoriasis. The reported FDA action adds active psoriatic arthritis to the product’s approved uses described in the announcement.

Relevance for pharmaceutical sales conversations

For pharmaceutical and biotech sales professionals following dermatology and rheumatology, the update provides a new approved-indication development to track. The reported indication is limited to adults with active psoriatic arthritis.

Sales teams can distinguish the reported new use from the product’s prior reported use in moderate-to-severe plaque psoriasis. Securities described the approval as an expansion for Ilumya, with the product identified as tildrakizumab-asmn.

The announcement centers on a regulatory decision by the FDA. Stakeholders discussing the development can refer to the reported supplemental Biologics License Application approval, the adult active psoriatic arthritis population, and Ilumya’s previously reported plaque psoriasis indication.

Key event details

• Company: Sun Pharmaceutical Industries
• Product: Ilumya, or tildrakizumab-asmn
• FDA action: Approval of a supplemental Biologics License Application
• Reported approved population: Adults with active psoriatic arthritis
• Previously reported indication: Moderate-to-severe plaque psoriasis

According to Securities, the FDA approval is the reported regulatory milestone expanding Ilumya’s use to adults with active psoriatic arthritis.